ExpreS2ion to present in spring investor events
Hørsholm, Denmark, 15 May 2024 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") will participate in upcoming investor events.
By attending relevant industry and investor events, the company aims to increase the awareness of its technology platform and its exciting development pipeline. More information on each event and how to register is found below and on the Company’s website.
16 May 2024 | First quarter 2024 financial results webcast, hosted by HC Andersen Capital
10:00 CET | Virtual
ExpreS2ion CEO Bent Frandsen and CFO Keith Alexander will present the 2024 first quarter results and answer investors’ questions. More information and registration can be found on the H.C. Andersen Capital Events website.
30 May 2024 | The BioStock Global Forum
11:00 CET | Lund, Sweden
Bent Frandsen will present at The Global Forum 2024, an event focusing on international expansion, partnerships, and capital attraction. For those interested in participating, registration is available on the BioStock event website.
4 June 2024 | HC Andersen Capital Life Science Seminar
Virtual
CEO Bent Frandsen will be participating in the H.C. Andersen Life Science Seminar on June 4th, which presents a good opportunity for us to engage with the life science community and share our latest developments. Bent will be providing an update on ExpreS2ion, discussing our unique platform and giving insights into our pipeline. More information and registration can be found on the H.C. Andersen Capital Events website.
Certified Adviser
Svensk Kapitalmarknadsgranskning AB
For further information about ExpreS2ion Biotech Holding AB, please contact:
Bent U. Frandsen, CEO
Keith Alexander, CFO
E-mail: investor@expres2ionbio.com
About ExpreS2ion
ExpreS2ion is a biotechnology company that develops innovative vaccines for a healthier world. We want to transform healthcare by developing novel vaccines, that are life-saving and improving quality of life across the world. ExpreS2ion has developed the unique human clinical Phase III-validated technology platform, ExpreS2™, for fast and efficient development and production of the active material in vaccines. The platform, under the brand GlycoX-S2™, includes functionally modified glycosylation variants for enhanced immunogenicity and pharmacokinetics. Since 2010, ExpreS2ion has produced more than 500 proteins and virus-like particles (VLPs) in collaboration with leading research institutions and companies. ExpreS2ion develops novel VLP based vaccines in association with AdaptVac ApS, of which ExpreS2ion owns 34%. For additional information, please visit www.expres2ionbio.com.